Printer Friendly

PSYCHEMEDICS CORPORATION ANNOUNCES ENTRY INTO TREATMENT MARKET WITH DRUG TEST FOR METHADONE

 HOFFMAN ESTATES, Ill., Feb. 4 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PCMC) today announced that the company will embark on a new area of drug analysis with the addition of methadone to the list of drugs that are analyzed by Psychemedics' proprietary RIAH (radioimmunoassay of hair) drug testing technology.
 The announcement was made by Raymond C. Kubacki, Jr., president and chief executive officer of Psychemedics Corporation, who noted that with the addition of methadone as one of the drugs that can be detected by Psychemedics' hair analysis technology, the company can impact the drug treatment and rehabilitation market.
 According to Kubacki, methadone is one of the primary agents used in the treatment of heroin addiction. "Our ability to measure methadone levels with our proprietary technology will enable physicians to more effectively evaluate methadone treatment, relapse, dose optimization and compliance with the prescribed medication regimen," he said.
 The advantages of hair analysis as it relates to methadone were evaluated in two independent field studies performed at the Stapleford Drug and Alcohol Treatment Center in England and at Narcotic and Drug Research, Inc. in New York.
 Kubacki said, "Because methadone is widely used for treatment of heroin addicts both in the U.S. and England, we hope that this newest application of our proprietary technology will be received well in the marketplace."
 The new Psychemedics methadone test will join Psychemedics' commercial proprietary test for drugs of abuse that is presently marketed to the corporate sector. The company's test uses human hair instead of urine or blood to detect illegal drugs in the system. As a result of hair being nourished by an individual's bloodstream, should an individual ingest drugs, the residue of those drugs will be permanently captured in the hair, and remain there as the hair grows. Since hair grows at an approximate rate of a half inch a month, by clipping only an inch and a half of an individual's hair, Psychemedics is able to determine whether drugs have been used over a three month period, rather than the average three-day window of detection afforded by the more standard urinalysis procedure. In addition, other advantages to Psychemedics' process include ease of collection, shipping and storage, and difficulty in adulteration or beating the test.
 The company has steadily increased its roster of corporate clients, with more than 250 businesses currently utilizing Psychemedics' test for drug screening needs.
 -0- 2/4/93
 /CONTACT: Beverly Jedynak of Martin E. Janis & Company, Inc., 312-943-1100, for Psychemedics Corporation/
 (PCMC)


CO: Psychemedics Corporation ST: Illinois IN: MTC SU: PDT

BM -- CL003 -- 2744 02/04/93 08:09 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 4, 1993
Words:430
Previous Article:STATEMENT ISSUED BY BITUMINOUS COAL OPERATORS ASSOCIATION
Next Article:SHOPSMITH REPORTS FISCAL THIRD-QUARTER FINANCIAL RESULTS
Topics:


Related Articles
PSYCHEMEDICS ANNOUNCES NEW REGIONAL SALES MANAGER FOR MIDWEST REGION
PSYCHEMEDICS REPORTS RECORD FIRST QUARTER REVENUES
PSYCHEMEDICS HOLDS ANNUAL MEETING; COMPANY PRESIDENT LOOKS TO CONTINUED GROWTH IN FUTURE
PSYCHEMEDICS CORPORATION ANNOUNCES NEW DRUG TESTING SERVICE FOR CHILDREN
PSYCHEMEDICS APPOINTS WILLIAM THISTLE, VP/GENERAL COUNSEL; PIONEER OF PRE-EMPLOYMENT DRUG SCREENING POLICY IN GAMING INDUSTRY
Psychemedics Corporation Introduces Patented Hair Analysis Drug Testing Service in National Over-The-Counter Rollout at Walgreens Drug Stores;
Mirage Selects Psychemedics to Drug Test Potential Employees.
Canadian Patent Office Issues Psychemedics Patent.
Psychemedics Corporation Announces UK and European Sales and Marketing Alliance.
Psychemedics Data From Ecstasy Drug Testing Results Indicates an Even More Serious Problem.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters